Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Somatostatin analogs
11 evidence topics · 12 sources
Octreotide test, long-acting analogs, and off-label pasireotide for insulinoma: ENETS guidance
Risk of worsening hypoglycemia in metastatic insulinoma: ESMO guideline
Receptor expression, octreotide challenge, and pasireotide in insulinoma: clinical review
“Expression of the SSTR2 and SSTR5 is generally low in indolent insulinoma cells, but usually high in aggressive insulinomas (81).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SRLs can adequately suppress the pathologic insulin hypersecretion in patients with insulinomas that express SSTR2 (17, 70, 81, 82). A challenge with subcutaneous administration of the short-acting SRL octreotide, is generally recommended before switching to a long-acting formulation. This test is required to avoid and timely intervene for a paradoxical aggravation of hypoglycemia via the suppression of counterregulatory glucagon secretion in patients with insulinomas which lack SSTR2 expression (81–84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Cushing disease, acromegaly and in phase 2-3 studies in NET (including panNET), hyperglycemia (79%), and type 2 diabetes were important side effects observed with pasireotide because of its inhibitory effects on incretin release (86–92). However, until now, pasireotide has not been approved for the treatment of panNET. Anecdotal reports show successful control with pasireotide of hypoglycemia in patients with insulinoma (75, 93–97).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Octreotide response by somatostatin receptor subtype in insulinoma
“Octreotide was effective on hypoglycaemia in 10/17 patients. Octreoscan scintigraphy detected 4/17 insulinomas. sst2A receptor was detected in 7/17 insulinomas and sst5 in 15/17 insulinomas.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Octreotide is an effective treatment of hypoglycaemia in more than 50% of patients with insulinoma. Detection of responsive patients was better based on a positive short test with subcutaneous octreotide than on the results of Octreoscan scintigraphy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term octreotide in endogenous hyperinsulinism not treated by surgery
“Reasons for not undergoing surgery were: refusal (n = 3), old age with multiple diseases (n = 5), unlocalized insulinomas (n = 2), malignant unresectable insulinomas (n = 5), multiple insulinomas (n = 3) and diffuse beta-cell disease (n = 3). Hypoglycaemia was responsive to octreotide in 14 of the 21 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subcutaneous octreotide treatment was prolonged for > 6 months (7-144 months, 67 +/- 47 months) in 11 responsive patients. No tachyphylaxis was observed. However, the octreotide dose had to be increased in two patients after 3 and 18 months, respectively. Only one patient suffered from symptomatic biliary lithiasis after 3 years of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pasireotide for insulinoma-associated hypoglycemia: systematic review of published cases
“Of 490 identified studies, 137 were reviewed, and 17 cases from 13 studies met the inclusion criteria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pasireotide was never the initial treatment. The most common doses were 40 to 60 mg/month for pasireotide long-acting release and 0.6 mg/12 h for short-acting pasireotide. Six patients (35%) showed no improvement, 4 (23%) had partial improvement, and 7 (41%) had complete resolution. Patients with aggressive insulinomas had a lower response rate, with 55% showing no improvement compared to 16% in indolent cases. Larger tumors were significantly associated with poorer response (P = .043). Hyperglycemia was the most common side effect (n = 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Octreotide indications and glucose warning: octreotide long-acting prescribing information
Lanreotide antitumor indication and glucose warning: lanreotide prescribing information
Pasireotide indication and hyperglycemia warning: pasireotide prescribing information
Octreotide in NICTH: clinical review
“Diazoxide and octreotide have no role in NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Octreotide, a nonspecific somatostatin analog, has been used unsuccessfully in multiple cases (39, 91).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Octreotide among recovered and deceased patients with IGF-2-mediated NICTH
| Treatment | All cases | Recovered (n = 172) | Died (n = 51) | p-value |
|---|---|---|---|---|
| Octreotide | “18 (7.7%)”View highlighted excerpt for this quote | “9 (5.2%)”View highlighted excerpt for this quote | “9 (17.6%)”View highlighted excerpt for this quote | “.01”View highlighted excerpt for this quote |